Key points from article :
Lucid Genomics, a German healthtech startup, has secured €1.3 million in pre-seed funding to advance its AI-driven platform for diagnostics and biomarker identification. Emerging from the research of the Max Planck Institute for Molecular Genetics and Berlin's Charité University Hospital, Lucid Genomics focuses on analysing both coding and non-coding regions of the genome—particularly the often-overlooked "dark genome." This approach aims to unlock new insights into disease and biological processes that traditional genome analysis might miss.
The company’s founders, Uirá Souto Melo and Hossein Moeinzadeh, emphasize their unique expertise in DNA sequencing, AI, and the dark genome. Lucid’s machine learning algorithms are designed to identify genetic variations with greater accuracy by exploring the non-coding regions, which make up 98% of our DNA. This could lead to advancements in precision medicine, gene editing, and drug discovery.
The startup plans to use the new funding to refine its machine learning models and further develop its comprehensive DNA analysis platform. With a vision to transform clinical trials, disease screening, and drug discovery, Lucid Genomics is poised to make significant contributions to personalized medicine and the healthcare industry.
